Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

UroGen Pharma (URGN) EBIT (2017 - 2025)

UroGen Pharma's EBIT history spans 9 years, with the latest figure at $70.5 million for Q4 2025.

  • For Q4 2025, EBIT rose 354.76% year-over-year to $70.5 million; the TTM value through Dec 2025 reached -$35.3 million, up 63.54%, while the annual FY2025 figure was -$35.3 million, 63.54% up from the prior year.
  • EBIT reached $70.5 million in Q4 2025 per URGN's latest filing, up from -$27.4 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of $70.5 million in Q4 2025 to a low of -$41.4 million in Q2 2025.
  • Average EBIT over 5 years is -$15.7 million, with a median of -$22.0 million recorded in 2022.
  • Peak YoY movement for EBIT: tumbled 143.08% in 2023, then soared 354.76% in 2025.
  • A 5-year view of EBIT shows it stood at -$19.9 million in 2021, then surged by 270.28% to $33.9 million in 2022, then plummeted by 143.08% to -$14.6 million in 2023, then tumbled by 89.32% to -$27.7 million in 2024, then skyrocketed by 354.76% to $70.5 million in 2025.
  • Per Business Quant, the three most recent readings for URGN's EBIT are $70.5 million (Q4 2025), -$27.4 million (Q3 2025), and -$41.4 million (Q2 2025).